Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine + eltrombopag for treatment-naive transfusion-dependent non-severe aplastic anemia
ChiCTR2100043229Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine and eltrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Hematologic complete response rate at 24 weeks and Safety at 24 weeks. Started Feb 2021; status: recruiting.
02
Drugs
cyclosporineeltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2100043229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043229.